Zymeworks Announces Expansion of Zanidatamab Pivotal Trial in HER2-Amplified Biliary Tract Cancer in Asia in Collaboration With BeiGeneBusiness Wire • 12/01/20
Zymeworks Receives FDA Breakthrough Therapy Designation for HER2-Targeted Bispecific Antibody Zanidatamab in Patients with Biliary Tract CancerBusiness Wire • 11/30/20
Zymeworks Receives Orphan Drug Designation From the European Commission for HER2-Targeted Bispecific Antibody Zanidatamab in Patients With Gastric CancerBusiness Wire • 11/19/20
Zymeworks and ALX Oncology Announce Clinical Collaboration Evaluating Zanidatamab with the CD47 Blocker ALX148 in Patients with Advanced HER2‑Expressing Breast CancerBusiness Wire • 11/16/20
ImmunoPrecise Announces New Multi-Specific SARS-CoV-2 Antibody Collaboration with ZymeworksPRNewsWire • 09/17/20
Zymeworks Inc. (ZYME) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 ReleaseZacks Investment Research • 07/31/20
Earnings Preview: Zymeworks Inc. (ZYME) Q3 Earnings Expected to DeclineZacks Investment Research • 10/29/19
Cancer Results to Watch at This Weekend’s European Society of Medical Oncology CongressThe Motley Fool • 09/27/19